WIL Research

WIL Research was a leading global contract research organization (CRO) providing non-clinical safety assessment and drug development services to the pharmaceutical, biotechnology, chemical, and agrochemical industries. The company specialized in toxicology, developmental and reproductive toxicology (DART), neurotoxicology, and inhalation toxicology, alongside bioanalytical and analytical chemistry services. With major facilities in the United States and Europe, WIL Research supported clients through the regulatory submission process for new drug candidates and chemical products. In 2016, the company was acquired by Charles River Laboratories for approximately $585 million, significantly expanding Charles River's global footprint and service capabilities in safety assessment. Prior to its acquisition, it operated as a portfolio company of Behrman Capital and was recognized for its high-quality scientific expertise and regulatory compliance.